Abstract:Purpose of Review
Aim of our systematic review is to evaluate and summarize the efficacy and safety of tadalafil alone or in combination with tamsulosin for the management of lower urinary tract symptoms (LUTS)/benign prostatic hyperplasia (BPH) and erectile dysfunction (ED).
Recent Findings
Daily tadalafil, in particular 5 mg, according to retrieved studies, appears to be both safe and effective in treating LUTS/BPH and ED, compared with placebo or tamsulosin. The combination of daily tadalafil 5 mg and tam… Show more
“…These include sildenafil, tadalafil, vardenafil, and avanafil, which differ for bioavailability, pharmacokinetics, affinity, and selectivity for PDE isoenzymes. Sildenafil is mostly used on demand, due to its short bioavailability, while tadalafil can be used daily and could be preferred in patients with contemporary benign prostatic hyperplasia [33]. It is noteworthy that PDE5 is involved in the intracellular signaling of insulin.…”
Diabetes mellitus (DM) is a widespread chronic disease with a prevalence that is expected to further increase in the near future. The classical management of DM includes the normalization of the glycometabolic profile and the evaluation of cardiac and cerebral vascular health by the intervention of an array of different specialists. However, so far, sexual dysfunctions are still a neglected complication in patients with DM, although there is an elevated prevalence of this long-term complication in male and female patients. Furthermore, some of them may represent a sign of vascular alteration and/or hypogonadism and require timely management to prevent the onset of major adverse cardiac events. This narrative review briefly summarizes the current evidence on epidemiology, pathogenesis, diagnosis, and therapy of erectile dysfunction in male patients with DM to support diabetologists in clinical practice.
“…These include sildenafil, tadalafil, vardenafil, and avanafil, which differ for bioavailability, pharmacokinetics, affinity, and selectivity for PDE isoenzymes. Sildenafil is mostly used on demand, due to its short bioavailability, while tadalafil can be used daily and could be preferred in patients with contemporary benign prostatic hyperplasia [33]. It is noteworthy that PDE5 is involved in the intracellular signaling of insulin.…”
Diabetes mellitus (DM) is a widespread chronic disease with a prevalence that is expected to further increase in the near future. The classical management of DM includes the normalization of the glycometabolic profile and the evaluation of cardiac and cerebral vascular health by the intervention of an array of different specialists. However, so far, sexual dysfunctions are still a neglected complication in patients with DM, although there is an elevated prevalence of this long-term complication in male and female patients. Furthermore, some of them may represent a sign of vascular alteration and/or hypogonadism and require timely management to prevent the onset of major adverse cardiac events. This narrative review briefly summarizes the current evidence on epidemiology, pathogenesis, diagnosis, and therapy of erectile dysfunction in male patients with DM to support diabetologists in clinical practice.
“…Although these drug treatments are effective, they can cause troublesome adverse reactions, such as hypotension, dizziness, and sexual dysfunction (7,8). Tadalafil, one of the phosphodiesterase type 5 inhibitors (PDE5Is) used to improve the symptoms of erectile dysfunction (ED), has been increasingly investigated and gained approval for the treatment of BPH in many countries since 2011 (9). This is mainly because PDE5Is are believed to likely act mainly by increasing the concentration of nitric oxide (NO), which improves the activity of intracellular cyclic guanosine monophosphate (cGMP) (10).…”
Section: Introductionmentioning
confidence: 99%
“…Although these drug treatments are effective, they can cause troublesome adverse reactions, such as hypotension, dizziness, and sexual dysfunction ( 7 , 8 ). Tadalafil, one of the phosphodiesterase type 5 inhibitors (PDE5Is) used to improve the symptoms of erectile dysfunction (ED), has been increasingly investigated and gained approval for the treatment of BPH in many countries since 2011 ( 9 ).…”
Section: Introductionmentioning
confidence: 99%
“…This system is collectively called the NO-cGMP signaling pathway, and its activation could lead to the relaxation of smooth muscle in the detrusor, bladder neck, and prostate ( 10 ). In addition, PDE5Is not only ameliorate intraprostatic inflammation-associated BPH but also improve tissue oxygenation and blood supply and thereby playing a vital part in alleviating LUTS ( 9 , 11 ).…”
Background: Tadalafil has been approved for the treatment of benign prostatic hyperplasia (BPH) for nearly 10 years. However, there are insufficient evidence-based studies of the efficacy and safety of tadalafil in treating lower urinary tract symptoms of BPH (LUTS/BPH).Objective: To evaluate the therapeutic effect and clinical safety of tadalafil monotherapy (5 mg once daily for 12 weeks) for LUTS/BPH.Methods: A total of 13 studies (15 randomized clinical trials [RCTs]) were extracted from the following databases: PubMed, Cochrane Central Register of Controlled Trials, Embase, and Web of Science for the period up to July 2021. The quality of the included RCTs was evaluated independently by two authors, who, respectively, extracted data according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses principles. Conflicts were settled by a discussion with two-third of senior authors. All data analyses were conducted by the Review Manager, version 5.4.Results: Regarding efficacy, 12-week trials indicated that 5 mg once daily tadalafil showed a significantly lower and, consequently, better total International Prostate Symptom Score (IPSS) than the placebo did (mean difference [MD]: −1.97, 95% CI: −2.24 to −1.70; P < 0.00001). In addition, significant differences were found between the tadalafil regimen and the placebo in the IPSS voiding subscore (MD: −1.30, 95% CI: −1.48 to −1.11; P < 0.00001), the IPSS storage subscore (MD: −0.70, 95% CI: −0.82 to −0.58; P < 0.00001), the IPSS quality of life (MD: −0.29, 95% CI: −0.35 to −0.22; P < 0.00001), and BPH impact index (MD: −0.58, 95% CI: −0.76 to −0.40; P < 0.00001). The safety analysis did not show a significant difference in serious adverse events between the two groups (risk ratio: 1.27, 95% CI: 0.80–2.01; P = 0.31), although the adverse events occurred at a higher incidence in the tadalafil group than in the placebo.Conclusions: This study demonstrates that once daily 5 mg tadalafil is a potentially effective and safe treatment choice with excellent tolerability for patients with LUTS/BPH.Systematic Review Registration: Identifier (CRD42021228840).
“…Furthermore, tadalafil 5 mg daily treatment as monotherapy or in combination with α-blockers have shown efficacy in treating both LUTS and ED. Sebastianelli et al indicated that tadalafil 5 mg should be considered a primary treatment option for patients with LUTS/BPH and ED with an excellent tolerability, safety, and effectiveness profile, both alone or in combination with tamsulosin 0.4 mg ( 5 ). Tadalafil is not just a treatment alternative to other established drugs for LUTS that have some sexual adverse events associated with their use, it is the only drug that can treat both ED and LUTS at the same time ( 6 ).…”
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.